MedTrace Logo

EXercise Capacity and TRAinability in Type 2 Diabetes (EXTRA-T2D)

NCT05860842 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-11-29

No results posted yet for this study

Summary

Type 2 Diabetes (T2D) is a condition characterized by acelerated aging and is associated to multiple comorbidities, and physical fragility and disabilitiy, all of which reduce life expectancy and quality of life. Physical exercise has been demonstrated to have metabolic and cardiovascular benefits in T2D. Also, lack of exercise and sedentary behavior are major predictors of cardiovascular morbidity and mortality and all-cause mortality. Some evidence suggests that individuals with T2D have a reduced exercise capacity and exercise tollerance compared to non-diabetic individuals.The reasons behind such difference are not thoroughly explored, but may be connected to acute and chronic effects of hyperglycemia. Reduced trainability might be a marker of early aging and physical disalbility. This study aims to define respiratory, cardiovascular, neuromuscular, inflammatory, hormonal and metabolic determinants of trainability in persons with T2D. Results will help to answer the question whether it is the low trainability that reduces exercise capacity or it is the low exercise participation that determines a low exercise capacity.

Conditions

Interventions

OTHER

exercise

Six months of supervised combined exercise training program, consisting of 2 sessions/wk of 75 min each, followed by a six-month period of follow-up. Each session will comprise a 5-min warm-up, 30-min endurance exercise, 30-min resistance exercise, 5-min flexibility and 5-min cool-down.

Sponsors & Collaborators

  • Università degli studi di Roma Foro Italico

    collaborator OTHER

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Giuseppe Pugliese, MD, PhD · University of Roma La Sapienza

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-02-28
Completion
2025-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05860842 on ClinicalTrials.gov